In response to growing demand worldwide, WuXi AppTec has commissioned two new peptide plants, one each at its Changzhou and Taixing sites in China. Both use digital operation systems with automated solvent delivery, in order to optimise production consistency, minimise human errors and reduce production cycle time.

This investment will increase the company’s total solid-phase peptide synthesis (SPPS) reactor volume to 32,000 litres. It also marks the official launch of Taixing as WuXi AppTec’s fifth API production sites.

WuXi STA has added two 2,000 L reactors and a large-scale continuous purification system for peptide manufacturing at its Changzhou campus, bringing the total reactor volume for solid-phase peptide synthesis to over 10,000 L. It has also added a new system that features 300-DAC twin columns for continuous purification of kilogram-scale peptides and oligonucleotides, with faster turnaround times and lower solvent consumption.

WuXi AppTec has announced a plan to build a new R&D and manufacturing site in Singapore at a cost of up to $1.4 billion. It will be created in stages over the next ten years, depending on the company’s business needs.

The company added that the site will serve “a critical role in its global network across Asia, Europe and North America”. It ill include “laboratories and facilities that provide a broad portfolio of R&D and manufacturing services” for the pharmaceutical industry.